Author:
Norden Andrew D.,Drappatz Jan,Muzikansky Alona,David Karly,Gerard Mary,McNamara M. Brenna,Phan Phuong,Ross Ainsley,Kesari Santosh,Wen Patrick Y.
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Neurology (clinical),Neurology,Oncology
Reference20 articles.
1. Wong ET, Hess KR, Gleason MJ, Jaeckle KA, Kyritsis AP, Prados MD, Levin VA, Yung WK (1999) Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials. J Clin Oncol 17:2572–2578
2. Yung W, Albright R, Olson J, Fredericks R, Fink K, Prados M, Brada M, Spence A, Hohl R, Shapiro W, Glantz M, Greenberg H, Selker R, Vick N, Rampling R, Friedman H, Phillips P, Bruner J, Yue N, Osoba D, Zaknoen S, Levin V (2000) A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse. Br J Cancer 83:588–593. doi: 10.1054/bjoc.2000.1316
3. Yung WK, Prados MD, Yaya-Tur R, Rosenfeld SS, Brada M, Friedman HS, Albright R, Olson J, Chang SM, O’Neill AM, Friedman AH, Bruner J, Yue N, Dugan M, Zaknoen S, Levin VA (1999) Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group. J Clin Oncol 17:2762–2771
4. Vredenburgh JJ, Desjardins A, Herndon JEII, Dowell JM, Reardon DA, Quinn JA, Rich JN, Sathornsumetee S, Gururangan S, Wagner M, Bigner DD, Friedman AH, Friedman HS (2007) Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin Cancer Res 13:1253–1259. doi: 10.1158/1078-0432.CCR-06-2309
5. Cloughesy T, Prados M, Wen P, Mikkelson T, Abrey L, Schiff D, Yung WK, Paleologos N, Nicholas MK, Dorr A, Zheng M, Dimery I, Friedman H (2007) A phase II, randomized, non-comparative clinical trial of bevacizumab alone or in combination with CPT-11 prolongs 6-month PFS in recurrent, treatment-refractory glioblastoma. Society for Neuro-Oncology 12th Annual Meeting
Cited by
116 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献